SERB Pharmaceuticals Acquires European and MENA Rights to Idefirix® from Hansa Biopharma in €115 Million Deal

SERB Pharmaceuticals has agreed to acquire exclusive development and commercialization rights to Idefirix® (Imlifidase) from Swedish biotech Hansa Biopharma AB (Nasdaq Stockholm: HNSA) for €115 million, the companies announced in Brussels on May 20, 2026. The transaction transfers authority over the asset across a broad stretch of Western and Northern Europe as well as the Middle East and North Africa, consolidating commercial and development responsibility under a single operator across those markets.

Geographic Reach of the Agreement

The territories covered by the deal span the European Union, the United Kingdom, Switzerland, Norway, Liechtenstein, and Iceland, alongside the MENA region. That footprint encompasses some of the world's most rigorously regulated pharmaceutical markets, where reimbursement frameworks and multi-jurisdiction approval requirements can shape commercial outcomes as decisively as clinical performance. By acquiring rights across that combined geography in a single transaction, SERB avoids the fragmented market-entry process that has complicated European launches for other specialty-therapy operators.

What the Deal Means for Hansa Biopharma

For Hansa Biopharma, listed on Nasdaq Stockholm under the ticker HNSA, the agreement converts its European and MENA rights to Idefirix® into €115 million of upfront capital. Rights-out structures of this kind have become a more prominent feature of European biotech strategy, allowing originator companies to monetize territorial assets while redirecting resources toward pipeline development or balance-sheet repair. The announcement did not describe any continuing commercial role for Hansa in the covered territories.

The Macro Context

The transaction reflects a wider dynamic playing out across European specialty pharma: mid-sized biotechs holding approved assets in multiple jurisdictions are increasingly willing to trade long-term commercial economics for immediate capital, particularly where building and sustaining multi-country infrastructure carries both cost and execution risk. Demand for de-risked, already-approved therapies with existing regulatory standing across the EU and adjacent markets has remained firm among well-capitalised acquirers, even as the broader financing environment for development-stage companies across the continent has tightened. For SERB, the Idefirix® acquisition sidesteps the regulatory runway and buys into an established commercial position across territories that, taken together, represent a substantial patient and payer base.